Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maëlys Touya

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Comparative Effectiveness Research|April 26, 2018
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USAMargarida Augusto, Mallik Greene, Maëlys Touya, et al.
Journal of Medical Economics|September 7, 2018
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United StatesMartin Cloutier, Mallik Greene, Maëlys Touya, et al.
Current Medical Research and Opinion|April 27, 2021
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support ProgramDebra F Lawrence, Janna Manjelievskaia, Lambros Chrones, et al.
Journal of Comparative Effectiveness Research|April 26, 2018
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USAMargarida Augusto, Mallik Greene, Maëlys Touya, et al.
Journal of Comparative Effectiveness Research|August 22, 2018
Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorderTingjian Yan, Mallik Greene, Eunice Chang, et al.
Current Medical Research and Opinion|October 24, 2017
All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychoticsTingjian Yan, Mallik Greene, Eunice Chang, et al.
BMC Psychiatry|March 2, 2022
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims dataMaëlys Touya, Debra F Lawrence, Anne Kangethe, et al.
BMC Health Services Research|August 7, 2021
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysisAnne Kangethe, Debra F Lawrence, Maëlys Touya, et al.
Journal of Medical Economics|September 13, 2017
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorderMallik Greene, Tingjian Yan, Eunice Chang, et al.
Advances in Therapy|September 13, 2018
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims DataTingjian Yan, Mallik Greene, Eunice Chang, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Comparative Effectiveness Research|April 26, 2018
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USAMargarida Augusto, Mallik Greene, Maëlys Touya, et al.
Journal of Medical Economics|September 7, 2018
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United StatesMartin Cloutier, Mallik Greene, Maëlys Touya, et al.
Current Medical Research and Opinion|April 27, 2021
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support ProgramDebra F Lawrence, Janna Manjelievskaia, Lambros Chrones, et al.
Journal of Comparative Effectiveness Research|April 26, 2018
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USAMargarida Augusto, Mallik Greene, Maëlys Touya, et al.
Journal of Comparative Effectiveness Research|August 22, 2018
Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorderTingjian Yan, Mallik Greene, Eunice Chang, et al.
Current Medical Research and Opinion|October 24, 2017
All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychoticsTingjian Yan, Mallik Greene, Eunice Chang, et al.
BMC Psychiatry|March 2, 2022
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims dataMaëlys Touya, Debra F Lawrence, Anne Kangethe, et al.
BMC Health Services Research|August 7, 2021
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysisAnne Kangethe, Debra F Lawrence, Maëlys Touya, et al.
Journal of Medical Economics|September 13, 2017
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorderMallik Greene, Tingjian Yan, Eunice Chang, et al.
Advances in Therapy|September 13, 2018
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims DataTingjian Yan, Mallik Greene, Eunice Chang, et al.
Pageof 3